Navigation Links
Researchers Link Bacteria Destroying Proteins to Alzheimer's Treatment

owed that the antibodies prevent this from happening by reducing accumulation of the amyloid beta proteins in vesicles inside the cell called endosomes.

"A lot of research has been done on protein clusters outside nerve cells," Gouras says. "In this study, we investigated for the first time what happens inside the cells and how antibodies can help prevent clusters from forming."

The researchers also found that the antibodies helped restore communication between nerve cells. In Alzheimer's patients, the protein clusters alter parts of the cell surfaces - the synapses - that help nerve cells talk to one another. As a result, thoughts are not transmitted, memory is lost, and new learning is hindered. But Gouras and his team showed that the antibodies cleared the protein clusters and helped cells talk to one another again.

Over the past seven years, research results on the use of antibodies against Alzheimer's disease have been so promising that two pharmaceutical companies, Ireland's Elan Corp. and U.S. partner Wyeth, have been conducting clinical trials of a potential vaccine. Although the first trials were stopped when 6 percent of the patients developed encephalitis - an inflammation of brain tissue - other clinical tests on the treated patients have been encouraging. In the second half of this year, the two companies will test a potential drug, called Bapineuzumab, on patients with mild to moderate Alzheimer's symptoms.

If successful, these trials could result in a new type of vaccine containing antibodies that would directly attack the amyloid beta protein clusters. Unlike common vaccines, which, in this case, would contain pieces of amyloid beta proteins and would stimulate the immune system to produce antibodies, the new vaccine would directly provide the antibodies to patients.

"These new developments are encouraging, but possible side effects may arise," Gouras said.

He added th
'"/>




Page: 1 2 3

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
(Date:5/12/2008)...CHARLOTTE, N.C., May 12 /PRNewswire-FirstCall/ -- ...e provider focused on high acuity health care,serv... cardiovascular,disease, today announced that Art ...rrently Interim Chief Financial Officer, has been ...nt effective immediately., "In his new role, Art ...
(Date:5/12/2008)... Reports Record Quarterly Sales of over $2...FirstCall/ -- Medifast, Inc.,(NYSE: MED ) announc...eriod,ended March 31, 2008., Financial highligh... 25%;, -- Gross margins increased to 75.8% vs. 74...r Life experienced sales increase of 63% year-...
(Date:5/11/2008)...HUDSON, N.H., May 12 /PRNewswire/ -- Atrium Medica...g a voluntary and precautionary recall of,selected...cic Drainage,Catheters. Limited lots of Atrium hep...ufactured with heparin found to have been contamin... The patient risk associated,with the presence of ...
(Date:5/11/2008)...COVER: "The O Team" (p. 20). Senior White House Co... campaign team, looking at the presidential,candid...,re all getting,ready for the coming mud war with ...insist that the race will be about the big issues ...idates over Iraq and the economy.,They,re also rea...
Breaking Medicine News(10 mins):Health News:MedCath Names Parker to New Finance Post 2Health News:Medifast Announces First Quarter 2008 Financial Results 2Health News:Medifast Announces First Quarter 2008 Financial Results 3Health News:Medifast Announces First Quarter 2008 Financial Results 4Health News:Medifast Announces First Quarter 2008 Financial Results 5Health News:Medifast Announces First Quarter 2008 Financial Results 6Health News:Medifast Announces First Quarter 2008 Financial Results 7Health News:Medifast Announces First Quarter 2008 Financial Results 8Health News:Atrium Initiates Voluntary Recall Action Regarding HYDRAGLIDE(TM) Brand Heparin-Coated Thoracic Drainage Catheters Used for Autotransfusion During Cardiopulmonary Bypass Surgery 2Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 2Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 3Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 4Health News:NEWSWEEK: Media Lead Sheet/May 19, 2008 Issue (on newsstands Monday, May 12, 2008) 5
...heimer’s disease have shown that it seems to stop ...esults boost hopes that such vaccines could delay ...s reduces the build-up of protein deposits in mous...f Alzheimer’s diseases. The pharmaceutical company...
...aggressive and almost impossible to handle at time...ncern over the way the children of today are growi...ing for help. Things are no better in India. With ...ids seem to know all at a very young age and many ...
...ed that two antioxidants in black pepper and turme...ect the bacterial DNA from damage by irradiation i... have radio protective effect and protecting organ... megaterium organisms (taken for study) against of...
... for anyone to buy contraceptives via Internet. So...cations and side effects and in most cases these a... these are now available through the Internet. How... these contraceptives after placing an order throu...
Other Medicine News:
(Date:5/8/2008)... May 8 /- Go Healthy (Pink ...clinical trials with Cholesterade (R),in three med...oup of 200,patients in 6 centers around the countr...ute at The Methodist Hospital in the Texas Medical...yan was formerly the Team,Physician for the Housto...
(Date:5/7/2008)...Study to Evaluate Preferred Induction Dosing Regim...ion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today an...,division of Wyeth (NYSE: WYE ), has commenced pa...f TRU-015 in patients with rheumatoid arthritis,(R...ticals is developing,TRU-015, SBI-087 and other CD...
(Date:5/7/2008)...ON, May 7 /- Shire plc (LSE...rmaceutical company, today,announced findings from...,treatment differences with DAYTRANA(TM) (methylph... aged 6 to 12 years with Attention Deficit,Hyperac...ysis reaffirmed,that DAYTRANA has an established s...
(Date:5/7/2008)...ON, May 7 /- Shire plc (LSE...rmaceutical company, presented,today at a major sc... trial,results of INTUNIV, a selective alpha-2A-ag...ily medication, which is being evaluated for the,t...ractivity Disorder,(ADHD). The data demonstrated t...
Breaking Medicine Technology:Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 2Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 3Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 4Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 5Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose 6Clean to Ease Allergy and Asthma Symptoms 461 1Clean to Ease Allergy and Asthma Symptoms 461 2National Patient Safety Foundation Partners with Vocera Communications 457 1National Patient Safety Foundation Partners with Vocera Communications 457 2Toxic Mold May Pose Health Threat to Pets 453 1Toxic Mold May Pose Health Threat to Pets 453 2New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 1New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 2New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 3New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 4New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 5New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 6New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition 338 7
...OS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHA...the presentation of two,posters at the XIth Annual... Greece from June 25-28th, 2007. The meeting highl...reatment of multiple,myeloma. ZIOPHARM is presenti...g data that further elucidates its unique,mechanis...
...esults also show significant additional protection...18 with the GSK cervical,cancer candidate vaccine,.../ -- Results,from an interim analysis of a Phase I...e cervical cancer candidate vaccine,provides up t...rous,lesions caused by the most common types of hu...
Other Medicine Technology:ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7
CVMstat® provides leading edge information on hundreds of topics involving all aspects of cardiovascular medicine, including sections on diagnosis and management of peripheral arterial and venou
Unbound Surgery, published by Unbound Medicine is an innovative digital resource that combines evidence-based clinical content and leading edge technology. It offers comprehensive information that is
Sages™ is the handheld version of The Sages Manual, a reference for the fundamentals of Laparoscopy and GI Endoscopy. It is a classic manual from the world's most pioneering society of minimally
This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards.
Medicine Products: